Congress Said No to NIH Restructuring. It Is Happening Anyway.

On February 3, 2026, Congress passed a full-year spending bill that explicitly preserved funding for all 27 National Institutes of Health institutes and centers. Every restructuring proposal — the White House plan to consolidate to 8 entities, the House Energy and Commerce Committee's version reducing to 15, the Heritage Foundation's block grant model — was rejected. The bipartisan message was unambiguous: do not restructure NIH.

Weeks later, the restructuring is proceeding anyway. Not through legislation, but through a systematic series of administrative actions that are reshaping the agency from within — eliminating offices, centralizing funding decisions, gutting the peer review system, and redirecting research priorities — all without a single congressional vote.

For the roughly 300,000 researchers whose careers depend on NIH funding, the question is no longer whether the agency will change. It is whether they understand what is actually changing, versus what Congress said should change.

The Restructuring That Didn't Need a Vote

The traditional understanding of how federal agencies change goes like this: Congress authorizes, Congress appropriates, the executive implements. NIH restructuring requires legislation — moving billions in appropriations, merging statutory entities, changing reporting structures. That is why every modern NIH reorganization, from the creation of NIAID to the establishment of the National Center for Advancing Translational Sciences, has gone through Congress.

What is happening now operates on a different logic. Instead of proposing structural changes that require legislative approval, the administration is using personnel actions, policy directives, and budget execution decisions to achieve functionally identical outcomes.

The pattern repeats across multiple fronts.

Eliminating offices through personnel actions. The Sexual and Gender Minority Research Office — established in 2015 and mandated by the 21st Century Cures Act — effectively ceased operations when seven staff members were placed on indefinite administrative leave in March 2025. No announcement was made. No legislative action was taken. The office was not formally closed; it simply stopped functioning because its employees were removed. For researchers studying health disparities in LGBTQ+ populations — a field with $64 million in annual NIH funding — the office that coordinated their portfolio vanished without a hearing.

Dismantling the peer review system. All institute- and center-run review panels have been eliminated, with many of the overseeing scientists laid off or reassigned. These panels previously handled 22% of the approximately 66,000 annual grant applications NIH receives, providing the specialized expertise that standard Center for Scientific Review study sections often lack. Disease-specific institutes like the National Cancer Institute and the National Eye Institute ran their own review panels precisely because their research portfolios required reviewers with deep domain knowledge that generalist panels could not provide.

The consolidation centralizes all review under the Center for Scientific Review and shifts funding decision authority upward — away from individual institute directors who historically exercised scientific judgment over their portfolios, and toward central leadership with different priorities.

Redirecting institute missions. At NIAID, staff have been directed to remove "biodefense" and "pandemic preparedness" language from research priority documents. Long-term disease surveillance modeling programs have been deprioritized. This does not require closing NIAID — Congress explicitly preserved it. But changing what NIAID funds and studies achieves a similar outcome to eliminating the pandemic preparedness functions that the administration targeted in its restructuring proposals.

Centralizing and reducing funding announcements. Individual institute websites are being consolidated into a single centralized page. Institutes are losing the authority to issue their own specialized Funding Opportunity Announcements — the mechanism through which they target specific research gaps and emerging scientific questions. Central leadership approval is now required for all new FOAs, with a stated goal of reducing specialized funding opportunities by at least 50%.

For researchers, this is the change that matters most at the operational level. NIH's 27 institutes issue hundreds of targeted FOAs annually — Program Announcements, Requests for Applications, and Notices of Special Interest — that signal where funding is available and what scientific questions the agency wants answered. Cutting this infrastructure in half does not just reduce bureaucracy. It eliminates the primary mechanism through which NIH communicates with the research community about what it will fund.

What Has Already Changed for Grant Seekers

The administrative restructuring has produced concrete, measurable effects on the grant landscape that researchers are navigating right now.

Grant awards have slowed dramatically. Despite Congress appropriating $48.7 billion for NIH in the FY2026 spending bill, the Office of Management and Budget has been slow to authorize the release of funds. The agency has received approximately one-third of its budget, and new grant awards have dropped to a fraction of normal volume. Last year, NIH issued 24% fewer new grants than its ten-year average — not because Congress cut funding, but because administrative processes delayed the flow of appropriated money to investigators.

The "Unified NIH Funding Strategy" replaces paylines. Historically, each institute set its own payline — the percentile cutoff above which applications received funding. This gave institute directors the flexibility to fund applications that matched their scientific priorities, even when percentile scores varied. The new unified strategy replaces paylines with multiple competing criteria, effectively transferring funding decisions from scientific program officers to a centralized process with different evaluation priorities. Presidential appointee approval is now required for every contracting action.

Specialized funding opportunities are disappearing. As institutes lose the authority to issue their own FOAs, the specific research areas they historically funded through targeted announcements are losing their dedicated funding channels. A researcher whose work aligns with a specialized PA from the National Institute of Neurological Disorders and Stroke may find that the PA no longer exists, and the parent R01 mechanism — while still available — lacks the programmatic signaling that previously guided reviewers and funding decisions.

Three Research Areas Facing the Sharpest Impact

While every NIH-funded researcher feels the effects of slower awards and centralized decision-making, three areas face disproportionate risk from the administrative restructuring.

Health disparities research. The National Institute on Minority Health and Health Disparities was among the institutes the White House proposed eliminating. Congress preserved it, but the removal of specialized review panels, the consolidation of FOAs, and the defunding of offices like the Sexual and Gender Minority Research Office collectively reduce the institutional infrastructure that supports health disparities science. Investigators in this space should expect fewer targeted funding opportunities and less institutional advocacy within NIH for their portfolios.

Global health and biodefense. NIAID's mission redirection away from pandemic preparedness and biodefense language, combined with the Fogarty International Center's proposed elimination (preserved by Congress but operationally sidelined), signals a contraction of NIH's international and infectious disease portfolio. Researchers conducting global health surveillance, international clinical trials, or biodefense-adjacent basic research should monitor NIAID FOAs carefully — the available topics may shift substantially over the next 12 months.

Complementary and integrative health. The National Center for Complementary and Integrative Health was another proposed elimination target. While Congress preserved its funding, the center's ability to issue specialized FOAs and advocate for its research portfolio within the centralized NIH structure is diminished. Investigators studying acupuncture mechanisms, mind-body interventions, or natural product pharmacology may find their work harder to fund through a unified review system that prioritizes different criteria.

Strategic Responses for Researchers

The administrative restructuring creates a funding environment that rewards different strategies than the one NIH-funded researchers have historically navigated. Adapting requires understanding what has actually changed — not what Congress said should or should not change, but what is happening operationally.

Diversify beyond NIH immediately. This is not aspirational advice. Researchers who depend entirely on NIH R01 funding face a structurally narrowed pipeline — fewer new awards, slower disbursement of appropriated funds, and reduced specialized funding opportunities. The Department of Defense's basic research programs (MURI, DURIP, Young Investigator Programs) fund university research at substantial scale. NSF, despite its own budget pressures, maintains independent peer review and targeted solicitations. Private foundations — Howard Hughes Medical Institute, the Simons Foundation, the Chan Zuckerberg Initiative — operate entirely outside the federal system. Building a multi-source funding portfolio is now a survival strategy, not a luxury.

Track the FOA landscape actively. As NIH consolidates and reduces its specialized funding announcements, the remaining FOAs become more valuable and more competitive. Researchers who historically waited for NIH to signal interest in their area through Notices of Special Interest or Program Announcements need to shift to active surveillance of what is being issued — and what is not being renewed. The absence of an FOA in your area is itself a signal.

Strengthen state and institutional support. Multiple states are launching their own research funding programs specifically to backstop NIH uncertainty. Massachusetts's $400 million DRIVE initiative, New York's Empire Biomedical Research Institute proposal, Texas's $3 billion DPRIT for dementia research, and California's SB 607 bond measure all represent state-level funding that does not depend on federal administrative decisions. Researchers at institutions in these states should engage with the application processes now — before the first rounds are fully subscribed.

Build collaborative and interdisciplinary proposals. The centralized review system, whatever its flaws, will likely favor proposals that span multiple research areas — precisely because centralized reviewers are evaluating across a broader portfolio than institute-specific panels did. Proposals that connect to multiple NIH strategic priorities, involve multiple disciplines, and demonstrate translational potential may navigate the unified system more successfully than narrowly focused basic science proposals that relied on sympathetic specialist reviewers.

Document the impact. Congressional staff and oversight bodies need evidence of how administrative actions are affecting research operations. Researchers who lose funding due to delayed awards, eliminated FOAs, or changed review criteria should document the specific mechanisms — not as political advocacy, but as factual records of what happened to appropriated funds that Congress intended to support their work. Professional societies, university government affairs offices, and organizations like FASEB and COGR are actively collecting this information.

The Precedent Problem

What is happening at NIH extends beyond science funding policy. The administrative restructuring demonstrates a mechanism for reshaping federal agencies when legislative authority cannot be obtained — using personnel actions instead of organizational changes, budget execution delays instead of appropriations cuts, and policy directives instead of statutory amendments.

Congress appropriated $48.7 billion for NIH and rejected every restructuring proposal. The money is technically available. The institutes are technically intact. But the operational infrastructure that converts congressional appropriations into scientific progress — the peer review panels, the specialized FOAs, the institute-level scientific judgment, the program officers who serve as the connective tissue between funded investigators and agency leadership — is being systematically weakened.

For researchers, the practical implication is clear: the NIH they are applying to in 2026 is not the same agency they applied to in 2024, regardless of what the appropriations numbers say. The funding is there. The mechanisms for distributing it are changing. And the researchers who recognize this gap between legislative intent and administrative reality will be better positioned to navigate what comes next than those who assume that congressional preservation of NIH's budget means preservation of NIH's function.

Granted tracks federal research funding opportunities across NIH, NSF, DoD, and DOE, helping researchers find active solicitations and monitor which programs are being renewed — and which are quietly disappearing.